Quantum BioPharma Announces Private Placement to Strengthen Voting Control and Fund Operations
Quantum BioPharma Ltd. is conducting a $750 private placement that will significantly increase voting control for its key executives while providing working capital for its neurodegenerative and metabolic disorder treatments.
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced a non-brokered private placement of up to 30 Class A multiple voting shares at $25 per share, aiming to raise gross proceeds of up to $750. The biopharmaceutical company, which focuses on developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, received shareholder approval for this offering on September 26, 2025.
The private placement is expected to be fully subscribed by entities controlled by Zeeshan Saeed and Anthony Durkacz, two key figures in the company's leadership. This transaction carries significant implications for corporate governance, as completion will increase the voting rights attached to the Class A shares to 75.27%. This restoration brings the voting control nearly back to its original level when Quantum BioPharma went public in 2018, representing a substantial consolidation of decision-making power within the company's founding leadership group.
According to the company's announcement, the proceeds from this financing will be allocated toward general working capital requirements. This funding comes at a critical time for Quantum BioPharma as it advances its pipeline of therapeutic candidates. The company's lead compound, Lucid-MS, developed through its wholly owned subsidiary Lucid Psycheceuticals Inc., represents a patented new chemical entity that has demonstrated potential in preclinical models to prevent and reverse myelin degradation—the underlying mechanism of multiple sclerosis.
Beyond its core research and development activities, Quantum BioPharma maintains strategic business interests through its ownership stake in Unbuzzd Wellness Inc., where it holds 20.11% ownership as of March 31, 2025. The relationship includes royalty payments of 7% of sales from the unbuzzd(TM) product until payments to Quantum BioPharma total $250 million, after which the royalty decreases to 3% in perpetuity. The company retains full rights to develop similar products for pharmaceutical and medical applications. Additional corporate activities are managed through FSD Strategic Investments Inc., another wholly owned subsidiary that handles loans secured by residential or commercial property. For investors seeking additional information, the company maintains its newsroom at https://ibn.fm/QNTM.
This private placement represents a strategic move to strengthen the company's financial position while consolidating voting control, potentially providing stability as Quantum BioPharma advances its clinical development programs. The transaction's structure, involving multiple voting shares rather than common equity, highlights the company's approach to balancing capital raising with maintaining strategic direction through its current leadership.